RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 119 filers reported holding RIGEL PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,133 | -76.2% | 1,975 | -50.0% | 0.00% | – |
Q2 2023 | $8,967 | +37.1% | 3,950 | +96.3% | 0.00% | – |
Q1 2023 | $6,539 | +81637.5% | 2,012 | -0.4% | 0.00% | – |
Q4 2022 | $8 | -99.9% | 2,020 | -0.3% | 0.00% | – |
Q3 2022 | $8,000 | 0.0% | 2,027 | 0.0% | 0.00% | – |
Q2 2022 | $8,000 | -50.0% | 2,027 | -50.4% | 0.00% | – |
Q1 2022 | $16,000 | +166.7% | 4,083 | +98.6% | 0.00% | – |
Q4 2021 | $6,000 | -33.3% | 2,056 | -0.3% | 0.00% | – |
Q3 2021 | $9,000 | +12.5% | 2,062 | -4.4% | 0.00% | – |
Q2 2021 | $8,000 | +33.3% | 2,157 | +16.8% | 0.00% | – |
Q1 2021 | $6,000 | +50.0% | 1,846 | +53.6% | 0.00% | – |
Q4 2020 | $4,000 | +100.0% | 1,202 | +9.8% | 0.00% | – |
Q3 2020 | $2,000 | 0.0% | 1,095 | 0.0% | 0.00% | – |
Q2 2020 | $2,000 | 0.0% | 1,095 | 0.0% | 0.00% | – |
Q1 2020 | $2,000 | – | 1,095 | – | 0.00% | – |
Q4 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q3 2019 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q4 2018 | $1,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |